You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: REAL PREVENTION LLC Topic: R41
DESCRIPTION provided by applicant The goal of this STTR R proposal is to transfer the technology from Rutgers University to REAL Prevention needed to adapt a substance use prevention media literacy curriculum for web based delivery in community organizations for commercialization Substance use increases in frequency and risk through mid adolescence yet most prevention interventions target ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: APPLIED STEMCELL, INC. Topic: 200
DESCRIPTION provided by applicant Gene correction therapy is one of the most important application directions in regenerative medicine Scientists are exploring various approaches to introduce targeted mutations corrections to pluripotent stem cells PSCs to establish disease models and or to develop therapeutic agents Emerging technologies such as Zinc Finger Nucleases ZFNs Transcription ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: COGNITION THERAPEUTICS, INC. Topic: NIA
DESCRIPTION provided by applicant Cognition Therapeutics Inc andapos s mission is to develop effective therapeutics for Alzheimerandapos s disease Recent scientific discoveries have identified oligomers of the brain protein Abeta as toxic culprits in the disease process Cognition has discovered therapeutic molecules that displace Abeta oligomers from neurons and block the downstream pathol ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: NeoVative, Inc. Topic: 400
DESCRIPTION provided by applicant andquot Code blue andquot the term used in hospitals to call for an immediate cardiopulmonary resuscitation CPR signals dire emergencies where medical errors can occur and lives can be lost Reviewing CPR performance of the code blue team is a cornerstone for improving outcomes Thorough and accurate recording of code blue events enable detailed reviews to ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: ADEPTHERA, LLC Topic: NICHD
DESCRIPTION provided by applicant Preeclampsia is a pregnancy specific hypertensive disorder that can lead to multi organ failure seizure and maternal death Preeclampsia is also responsible for as many as of premature births in the United States Although better neonatal care has improved the likelihood of preterm babies surviving many face increased mortality and serious long term mor ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: AFASCI, INC. Topic: NIDA
DESCRIPTION provided by applicant The abuse of illicit drugs such as cocaine marijuana and heroin remains a critical public health concern throughout the country and is associated with staggering economic and social consequences Cocaine remains the most frequently recorded illicit drug in emergency hospital visits and the leading cause of drug related deaths in the United States Since as hi ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: BioIncept, LLC Topic: NICHD
ABSTRACT Perinatal hypoxic ischemic encephalopathy HIE affects to infants per every born Mortality from HIE can be up to and approximately of survivors suffer significant long term disability including cerebral palsy epilepsy and developmental disorders Damage during the acute phase of HIE is caused by a deficit in oxygen and glucose in the brain However increasing evide ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.SBC: Acumen Pharmaceuticals, Inc Topic: NIA
In the United States in an estimated million people suffered from Alzheimer s disease AD with as many as being undiagnosed Alzheimer s Association Three stages of AD are proposed National Institute on Aging and the Alzheimer s Association preclinical AD mild cognitive impairment MCI due to AD and dementia due to AD The preclinical stage is proposed to begin ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
Use of EF2K inhibitors to inhibit tumor growth and sensitize cancer cells to existing chemotherapy treatmentSBC: LONGEVICA PHARMACEUTICALS, INC. Topic: 102
DESCRIPTION provided by applicant Eukaryotic elongation factor protein kinase eEF K is a ubiquitously expressed protein that belongs to a family of alpha kinases characterized by an andquot atypicalandquot kinase domain Our recent findings demonstrate that inhibition or genetic inactivation of eEF K protects normal tissues from cytotoxic effects of ionizing radiation and chemotherapeutic ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: SEACOAST SCIENCE, INC. Topic: NIEHS
Project Summary This Small Business Technology Transfer Phase I project proposes the development and optimization of a commercially viable novel polymer based radiation dosimeter for wide spread deployment The radiation dosimeter proposed herein is a disruptive technology with a significant market Although many commercial radiation dosimeters measure individual radiation load dose quantificatio ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health